Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 7/2017

01-07-2017 | Original Article

Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease

A multi-institutional treatment recommendation

Authors: Carsten Nieder, MD, Dirk De Ruysscher, MD, Laurie E. Gaspar, MD, Matthias Guckenberger, MD, Minesh P. Mehta, MD, Patrick Cheung, MD, Arjun Sahgal, MD

Published in: Strahlentherapie und Onkologie | Issue 7/2017

Login to get access

Abstract

Background

Practice guidelines have been developed for early-stage and locally advanced non-small cell lung cancer (NSCLC). However, many common clinical scenarios still require individualized decision making. This is true for locoregional relapse after initial stereotactic radiotherapy (stereotactic body radiation therapy or stereotactic ablative radiotherapy; SBRT or SABR), an increasingly utilized curative treatment option for stage I NSCLC.

Methods

A consortium of expert radiation oncologists was established with the aim of providing treatment recommendations. In this scenario, a case was distributed to six radiation oncologists who provided their institutions’ treatment recommendations. In this case, a patient developed local and mediastinal relapse after SABR (45 Gy, 3 fractions), comparable to the tumor burden in de novo stage IIIA NSCLC. Treatment recommendations were tabulated and a consensus conclusion was developed.

Results

Three institutions recommended evaluation for surgery. If the patient was not a surgical candidate, and/or refused surgery, definitive chemoradiation was recommended, including retreating the primary to full dose. European participants were more in favor of a non-surgical approach. None of the participants were reluctant to prescribe reirradiation, but two institutions prescribed doses lower than 60 Gy. Platinum-based doublets together with intensity-modulated radiotherapy were preferred.

Conclusion

The institutional recommendations reflect the questions and uncertainties discussed in current stage III guidelines. All institutions agreed that previous SABR is not a contraindication for salvage chemoradiation. In the absence of high-quality prospective trials for recurrent NSCLC, all treatment options recommended in current guidelines for stage III disease can be considered in clinical scenarios such as this.
Literature
1.
Kong FM, Cuneo KC, Wang L et al (2014) Patterns of practice in radiation therapy for non-small cell lung cancer among members of the American Society for Radiation Oncology. Pract Radiat Oncol 4:e133–141CrossRefPubMed
2.
Schanne DH, Nestle U, Allgäuer M et al (2015) Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. Strahlenther Onkol 191:125–132CrossRefPubMed
3.
Kelley KD, Benninghoff DL, Stein JS et al (2015) Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy. Radiat Oncol 10:120CrossRefPubMedPubMedCentral
4.
Nieder C, Andratschke NH, Guckenberger M (2015) A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question? Ann Transl Med 3:148PubMedPubMedCentral
5.
Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16:630–637CrossRefPubMedPubMedCentral
6.
Shaverdian N, Wang PC, Steinberg M, Lee P (2015) The patient’s perspective on stereotactic body radiation therapy (SBRT) vs. surgery for treatment of early stage non-small cell lung cancer (NSCLC). Lung Cancer 90:230–233CrossRefPubMed
7.
Farjah F, Lou F, Sima C, Rusch VW, Rizk NP (2013) A prediction model for pathologic N2 disease in lung cancer patients with a negative mediastinum by positron emission tomography. J Thorac Oncol 8:1170–1180CrossRefPubMed
8.
Cuaron J, Dunphy M, Rimner A (2013) Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer. Front Oncol 2:208CrossRefPubMedPubMedCentral
9.
Onishi H, Araki T, Shirato H et al (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multi-institutional study. Cancer 101:1623–1631CrossRefPubMed
10.
Onishi H, Shirato H, Nagata Y et al (2011) Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 81:1352–1358CrossRefPubMed
11.
Mehta N, King CR, Agazaryan N et al (2012) Stereotactic body radiation therapy and 3‑dimensional conformal radiotherapy for stage I non-small cell lung cancer: a pooled analysis of biological equivalent dose and local control. Pract Radiat Oncol 2:288–295CrossRefPubMed
12.
Mokhles S, Verstegen N, Maat AP et al (2015) Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. Lung Cancer 87:283–289CrossRefPubMed
13.
VanderMeer R, Chambers S, Van Dam A, Cutz JC, Goffin JR, Ellis PM (2015) Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care? Curr Oncol 22:272–278CrossRefPubMedPubMedCentral
14.
Woody NM, Stephans KL, Marwaha G, Djemil T, Videtic GM (2015) Stereotactic body radiation therapy for non-small cell lung cancer tumors greater than 5 cm: Safety and efficacy. Int J Radiat Oncol Biol Phys 92:325–331CrossRefPubMed
15.
Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S (2012) Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 13:802–809CrossRefPubMed
16.
Spratt DE, Wu AJ, Adeseye V et al (2016) Recurrence patterns and second primary lung cancers after stereotactic body radiotherapy for early-stage non-small cell lung cancer: implications for surveillance. Clin Lung Cancer 17:177–183CrossRefPubMed
17.
Van den Berg LL, Klinkenberg TJ, Groen HJ, Widder J (2015) Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. J Thorac Oncol 10:826–831CrossRefPubMed
18.
Ward MC, Oh SC, Pham YD et al (2016) Isolated nodal failure after stereotactic body radiotherapy for lung cancer: the role for salvage mediastinal radiotherapy. J Thorac Oncol 11:1558–1564CrossRefPubMed
19.
Verstegen NE, Lagerwaard FJ, Hashemi SM, Dahele M, Slotman BJ, Senan S (2015) Patterns of disease recurrence after SABR for early stage non-small-cell lung cancer: optimizing follow-up schedules for salvage therapy. J Thorac Oncol 10:1195–1200CrossRefPubMed
20.
Hamaji M, Chen F, Matsuo Y, Ueki N, Hiraoka M, Date H (2015) Treatment and prognosis of isolated local relapse after stereotactic body radiotherapy for clinical stage I non-small-cell lung cancer: importance of salvage surgery. J Thorac Oncol 10:1616–1624CrossRefPubMed
21.
Oberije C, De Ruysscher D, Houben R et al (2015) A validated prediction model for overall survival from stage III non-small cell lung cancer: toward survival prediction for individual patients. Int J Radiat Oncol Biol Phys 92:935–944CrossRefPubMedPubMedCentral
22.
Eberhardt WE, De Ruysscher D, Weder W et al (2015) 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol 26:1573–1588CrossRefPubMed
23.
Chang JY, Kestin LL, Barriger RB et al (2014) ACR Appropriateness Criteria® nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent. Oncology 28:706–710PubMed
24.
Ramnath N, Dilling TJ, Harris LJ et al (2013) Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e314S–340SCrossRefPubMed
25.
Willers H, Stinchcombe TE, Barriger RB et al (2015) ACR Appropriateness Criteria(®) induction and adjuvant therapy for N2 non-small-cell lung cancer. Am J Clin Oncol 38:197–205CrossRefPubMed
26.
Rodrigues G, Choy H, Bradley J et al (2015) Definitive radiation therapy in locally advanced non-small cell lung cancer: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol 5:141–148CrossRefPubMed
27.
Bezjak A, Temin S, Franklin G et al (2015) Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline. J Clin Oncol 33:2100–2105CrossRefPubMed
28.
Bradley JD, Paulus R, Komaki R et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:187–199CrossRefPubMedPubMedCentral
29.
Jalal SI, Riggs HD, Melnyk A et al (2012) Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol 23:1730–1738CrossRefPubMed
30.
De Ruysscher D, Faivre-Finn C, Le Pechoux C, Peeters S, Belderbos J (2014) High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. Lancet Oncol 15:e620–e624CrossRefPubMed
31.
Kruser TJ, McCabe BP, Mehta MP et al (2014) Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma. Am J Clin Oncol 37:70–76CrossRefPubMedPubMedCentral
32.
Amini A, Yeh N, Gaspar LE, Kavanagh B, Karam SD (2014) Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. Radiat Oncol 9:210CrossRefPubMedPubMedCentral
33.
Patel NR, Lanciano R, Sura K et al (2015) Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses. J Radiat Oncol 4:65–70CrossRefPubMed
34.
35.
Peulen H, Karlsson K, Lindberg K et al (2011) Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. Radiother Oncol 101:260–266CrossRefPubMed
36.
Kilburn JM, Kuremsky JG, Blackstock AW et al (2014) Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol 110:505–510CrossRefPubMedPubMedCentral
37.
Meng MB, Wang HH, Zaorsky NG et al (2015) Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. Oncotarget 6:15690–15703CrossRefPubMedPubMedCentral
38.
Kilburn JM, Lester SC, Lucas JT Jr et al (2014) Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer. J Thorac Oncol 9:572–576CrossRefPubMedPubMedCentral
39.
Oskan F, Becker G, Bleif M (2017) Specific toxicity after stereotactic body radiation therapy to the central chest: a comprehensive review. Strahlenther Onkol 193:173–184CrossRefPubMed
40.
Binkley MS, Hiniker SM, Chaudhuri A et al (2016) Dosimetric factors and toxicity in highly conformal thoracic reirradiation. Int J Radiat Oncol Biol Phys 94:808–815CrossRefPubMed
41.
Sumita K, Harada H, Asakura H et al (2016) Re-irradiation for locoregionally recurrent tumors of the thorax: a single-institution, retrospective study. Radiat Oncol 11:104CrossRefPubMedPubMedCentral
42.
Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Fløtten O, Aasebø U (2013) Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomized trial by the Norwegian Lung Cancer Study Group. Br J Cancer 109:1467–1475CrossRefPubMedPubMedCentral
43.
Machtay M, Paulus R, Moughan J et al (2012) Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol 7:716–722CrossRefPubMed
44.
Rajpara RS, Schreibmann E, Fox T et al (2014) Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer. Radiat Oncol 9:187CrossRefPubMedPubMedCentral
45.
De Ruysscher D, Faivre-Finn C, Nestle U et al (2010) European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 28:5301–5310CrossRefPubMed
46.
Nieder C, Pawinski A, Andratschke NH (2013) Combined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations. Front Oncol 3:176CrossRefPubMedPubMedCentral
47.
Fleckenstein J, Eschler A, Kremp K, Kremp S, Rübe C (2015) Dose distribution and tumor control probability in out-of-field lymph node stations in intensity modulated radiotherapy (IMRT) vs 3D-conformal radiotherapy (3D-CRT) of non-small-cell lung cancer: an in silico analysis. Radiat Oncol 10:178CrossRefPubMedPubMedCentral
48.
Flentje M, Huber RM, Engel-Riedel W et al (2016) GILT – a randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol 192:216–222CrossRefPubMed
49.
Lee SU, Moon SH, Cho KH et al (2016) Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas: Ablative dose PBT for NSCLC. Strahlenther Onkol 192:649–657CrossRefPubMed
Metadata
Title
Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease
A multi-institutional treatment recommendation
Authors
Carsten Nieder, MD
Dirk De Ruysscher, MD
Laurie E. Gaspar, MD
Matthias Guckenberger, MD
Minesh P. Mehta, MD
Patrick Cheung, MD
Arjun Sahgal, MD
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 7/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1130-0

Other articles of this Issue 7/2017

Strahlentherapie und Onkologie 7/2017 Go to the issue

Literatur kommentiert

Salvage-Radiotherapie mit antiandrogener Therapie nach Prostatektomie

Original Article

Small bowel protection in IMRT for rectal cancer

Original Article

Reirradiation for recurrent head and neck cancers using charged particle or photon radiotherapy

Original Article

Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer

Original Article

Patient-reported symptoms during radiotherapy

Literatur kommentiert

Konsolidierende Lokaltherapie verbessert progressionsfreies Überleben von Patienten mit oligometastasiertem NSCLC